Related Experiment Video

Updated: Mar 25, 2026

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
07:44

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction

Published on: March 25, 2022

7.0K

Primary Biliary Cirrhosis Beyond Ursodeoxycholic Acid

Christophe Corpechot1

  • 1Hepatology Department, Reference Center for Chronic Inflammatory Biliary Diseases (MIVB), French Network for Pediatric and Adult Rare Liver Diseases (FILFOIE), INSERM UMR_S938, Saint-Antoine Hospital (Assistance Publique-Hôpitaux de Paris) and Faculty of Medicine Pierre et Marie Curie, Paris 6 University, Paris, France.

Seminars in Liver Disease
|February 13, 2016
PubMed

Insights

Ursodeoxycholic acid is the primary treatment for primary biliary cirrhosis, but new therapies offer improved management. Early identification of high-risk patients is key for successful treatment strategies.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Pharmacology

Background:

  • Ursodeoxycholic acid (UDCA) is the sole approved drug for primary biliary cirrhosis (PBC).
  • Factors contributing to poor UDCA response and new therapeutic targets are emerging.
  • Novel agents show promise in improving prognostic markers for PBC patients.

Purpose of the Study:

  • To review current knowledge on managing primary biliary cirrhosis.
  • To propose a practical approach for selecting second-line therapies.
  • To guide clinicians in optimizing treatment strategies for PBC.

Main Methods:

  • Review of current literature on PBC pharmacotherapy.
  • Analysis of emerging treatment options and their efficacy.
  • Development of a decision-making framework for treatment selection.

Main Results:

  • Several novel agents (fibrates, budesonide, obeticholic acid) can improve prognostic markers.
  • Early identification of high-risk patients is crucial for adjunctive therapy.
  • Treatment choice should consider biochemical, histological, and tolerance profiles.

Conclusions:

  • New therapeutic targets offer significant opportunities to improve PBC management.
  • A personalized approach to second-line treatment selection is recommended.
  • Further comparative trials are needed to guide optimal therapeutic choices.

More Related Videos

Ileectomy-induced Bile Overaccumulation in Mouse Intestine06:55

Ileectomy-induced Bile Overaccumulation in Mouse Intestine

Published on: August 21, 2017

10.1K

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
475
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
896
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.3K
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
871
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
738
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
1.0K